B

Broncus Holding Corp
HKEX:2216

Watchlist Manager
Broncus Holding Corp
HKEX:2216
Watchlist
Price: 0.46 HKD -1.08% Market Closed
Market Cap: 242.5m HKD
Have any thoughts about
Broncus Holding Corp?
Write Note

Broncus Holding Corp
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Broncus Holding Corp
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
B
Broncus Holding Corp
HKEX:2216
Additional Paid In Capital
$593.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Additional Paid In Capital
ÂĄ724m
CAGR 3-Years
66%
CAGR 5-Years
46%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Additional Paid In Capital
ÂĄ2B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
40%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Additional Paid In Capital
ÂĄ6.9B
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Additional Paid In Capital
ÂĄ711.8m
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Additional Paid In Capital
ÂĄ13.9B
CAGR 3-Years
64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Broncus Holding Corp
Glance View

Market Cap
242.5m HKD
Industry
Health Care

Broncus Holding Corp. engages in provision of interventional diagnosis and therapeutics solutions. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-09-24. The firm's business includes providing diagnostic solutions, lung cancer treatment solutions, chronic obstructive pulmonary disease solutions and navigation platforms. The diagnostic solutions pruducts include FleXNeedle, ATV Sheath, ATV Balloon and others. The lung cancer treatment solutions products include InterVapor for lung cancer, H-Marker and others. The chronic obstructive pulmonary disease (COPD) solutions products include InterVapor for COPD and TLD Ablation System. The navigation platform products include Lungpoint, Lungpro, New Generation Navigation Platform and others.

Intrinsic Value
0.65 HKD
Undervaluation 29%
Intrinsic Value
Price
B

See Also

What is Broncus Holding Corp's Additional Paid In Capital?
Additional Paid In Capital
593.6m USD

Based on the financial report for Dec 31, 2023, Broncus Holding Corp's Additional Paid In Capital amounts to 593.6m USD.

What is Broncus Holding Corp's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 1Y
0%

Over the last year, the Additional Paid In Capital growth was 0%.

Back to Top